Loxo Oncology expects proceeds of $214 million from a public offering of stock next week, with the Stamford pharmaceutical company developing a treatment for cancers with specific gene abnormalities that can be targeted with minimal side effects.

Loxo priced the offering at $72 a share, with its shares having spiked from about $47 entering June after it announced clearance of an Investigational New Drug application to the Food & Drug Administration.

The company could gross another $34 million in any additional sales of stock by its underwriters to cover over-allotments.

Still in pre-revenue stage, Loxo lost $24.5 million in the first three months of 2017, leaving it with assets totaling just under $250 million.

Alex.Soule@scni.com; 203-842-2545; www.twitter.com/casoulman